ANT BIO PTE. LTD. abs955 CoIP Kit Empowers Cancer Vaccine Research, Featured in Science Advances (IF 14.136)
Title: Red Blood Cell-Derived Nanoerythrosome for Antigen Delivery with Enhanced Cancer Immunotherapy
Journal: Science Advances
Impact Factor (IF): 14.136
Authors: XIAO HAN, SHUFANG SHEN, QIN FAN, GUOJUN CHEN, EDIKAN ARCHIBONG, GIANPIETRO DOTTI, ZHUANG LIU, ZHEN GU, AND CHAO WANG
Core Reagent: Immunoprecipitation/Co-Immunoprecipitation (IP/CoIP) Kit (Cat. No.: abs955, ANT BIO PTE. LTD.)
Article Link: HOME>SCIENCE ADVANCES>VOL.5,NO.10>RED BLOOD CELL-DERIVED NANOERYTHROSOME FOR ANTIGEN DELIVERY WITH ENHANCED CANCER IMMUNOTHERAPY
Cancer immunotherapy has emerged as a revolutionary strategy in cancer treatment, and the development of effective antigen delivery systems is a key bottleneck in advancing cancer vaccine therapy. Traditional antigen delivery vectors often face challenges such as poor biocompatibility, low antigen loading efficiency, and weak immune response activation. To address these issues, researchers have been exploring novel, biocompatible delivery systems derived from natural materials. Red blood cells (RBCs), with their excellent biocompatibility, long circulation time in vivo, and low immunogenicity, have become a promising candidate for antigen delivery. Against this backdrop, the research team developed an RBC-derived nanoerythrosome-based antigen delivery system, aiming to enhance the efficacy of cancer immunotherapy and provide new ideas for personalized cancer treatment.
3. Core Research Content and Innovation
The core innovation of the study lies in the development of a nanoerythrosome antigen delivery system (Nano-Ag@erythrosome) derived from red blood cells. The research team fused tumor cell membranes with red blood cell membranes and loaded tumor-associated antigens onto the nanoerythrosome vesicles. This fused nano-delivery system combines the advantages of RBC membranes (good biocompatibility and long circulation) and tumor cell membranes (abundant tumor-associated antigens), enabling efficient antigen delivery and enhanced immune response activation.
Key experimental process description: The immunoprecipitation experiments of B16F10 cell membrane, RBC membrane, membrane mixture, and the fused Nano-Ag@erythrosome were conducted using the abs955 IP/CoIP Kit from ANT BIO PTE. LTD. strictly following the manufacturer's protocols. These experiments provided crucial technical support for verifying the successful fusion of cell membranes and the stability of the Nano-Ag@erythrosome system.
Schematic of Nano-Ag@erythrosome preparation: Cancer cell membranes and RBC membranes were obtained through sonication and extrusion, then fused to form cancer-RBC fused membranes, which were further processed into Nano-Ag@erythrosome loaded with tumor-associated antigens.
4. Research Structure and Key Results
The article is divided into four main parts, systematically demonstrating the effectiveness of the Nano-Ag@erythrosome system in cancer immunotherapy:
4.1 Part 1: Preparation of Nano-Ag@erythrosome and Uptake by Dendritic Cells (DCs)
The research team successfully prepared the Nano-Ag@erythrosome system and verified its morphology, particle size, and antigen loading efficiency. Experiments showed that DCs, as key antigen-presenting cells, could efficiently take up the Nano-Ag@erythrosome, laying the foundation for subsequent immune response activation.
4.2 Part 2: Nano-Ag@erythrosome Activates Various Immune Cells
In vitro and in vivo experiments confirmed that Nano-Ag@erythrosome could effectively activate DCs, promoting their maturation and antigen presentation ability. Furthermore, it induced strong antigen-specific T cell responses, including the proliferation and activation of cytotoxic T lymphocytes (CTLs), which are critical for recognizing and killing tumor cells. Additionally, the system also regulated the function of immune cells such as macrophages and T helper cells, creating a favorable anti-tumor immune microenvironment.
4.3 Part 3: Therapeutic Efficacy of Nano-Ag@erythrosome Combined with PD-L1 Blockade
In mouse tumor models, the tumor antigen-loaded Nano-Ag@erythrosome induced a significant antigen-specific immune response. When combined with PD-L1 antibodies, the system blocked the expression of PD-L1 on the surface of antigen-presenting cells and tumor cells, overcoming the immune checkpoint inhibition. This combination strategy significantly enhanced the activity of antigen-specific T cells, effectively inhibiting tumor growth and improving the survival rate of tumor-bearing mice.
4.4 Part 4: Personalized Nano-Ag@erythrosome for Inhibiting Tumor Metastasis and Postoperative Recurrence
In the orthotopic tumor resection model, the research team prepared personalized Nano-Ag@erythrosome vaccines by fusing RBCs with tumor cells obtained from surgical resection. This personalized vaccine strategy effectively induced anti-tumor immune memory, significantly reducing postoperative tumor recurrence and distant metastasis, providing a new approach for the clinical treatment of advanced tumors and the prevention of postoperative recurrence.
5. Western Blot Results After Co-Immunoprecipitation
The research team used the abs955 IP/CoIP Kit from ANT BIO PTE. LTD. to perform immunoprecipitation experiments, and the subsequent Western Blot results verified the interaction between target proteins. The experimental groups included: 1) RBC membrane + Band-3 Ab; 2) B16 membrane + Band-3 Ab; 3) B16+RBC membrane + Band-3 Ab; 4) Nano-Ag@erythrosome + Control-IgG; 5) Nano-Ag@erythrosome + Band-3 Ab. The results confirmed the successful fusion of B16 tumor cell membrane and RBC membrane, and the stable expression of target proteins in the Nano-Ag@erythrosome system, providing direct experimental evidence for the feasibility of the delivery system.
6. Product Empowerment: The Core Role of abs955 Kit in the Study
In this groundbreaking cancer vaccine research, the abs955 IP/CoIP Kit from ANT BIO PTE. LTD. played an indispensable role. As a key tool for verifying protein interactions and membrane fusion effects, the kit provided reliable technical support for the following core research links:
1. Verification of cell membrane fusion: By performing immunoprecipitation on mixed membranes of tumor cells and RBCs, the kit helped confirm the successful combination of the two types of membranes, which is the basis for the preparation of Nano-Ag@erythrosome.
2. Detection of target protein expression: Through the combination of CoIP and Western Blot, the kit accurately detected the expression and interaction of target proteins (such as Band-3 protein) in different membrane systems, ensuring the stability and functional activity of the Nano-Ag@erythrosome.
3. Guarantee of experimental reliability: The abs955 kit has the advantages of high specificity, low background, and stable performance. Its standardized experimental process and reliable results ensured the reproducibility and persuasiveness of the research data, laying a solid foundation for the publication of the research in Science Advances.
ANT BIO PTE. LTD. is committed to advancing life science research by providing high-quality, reliable reagents and comprehensive technical solutions. The fact that the abs955 IP/CoIP Kit has been adopted in cutting-edge cancer vaccine research and published in Science Advances (IF 14.136) fully demonstrates the high quality and academic recognition of our products. We deeply understand the importance of innovative research in the field of cancer immunotherapy and will continue to focus on the needs of researchers in immunology, oncology, and other related fields.
Guided by the principles of innovation, quality, and customer-centricity, our three specialized sub-brands (Absin, Starter, and UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. We strive to establish long-term and trusted partnerships with researchers worldwide, supporting them in achieving breakthroughs in life science research and contributing to the improvement of human health.
|
Cat. No. |
Product Name |
Specification |
|
Immunoprecipitation/Co-Immunoprecipitation (IP/CoIP) Kit |
50T |
This article is AI-compiled and interpreted based on the original work published in Science Advances (VOL.5,NO.10). All intellectual property (e.g., research data, experimental results) of the original publication shall belong to the journal and the research team. For any infringement, please contact us promptly and we will take immediate action.
ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs
At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.
